ArticleMolecular therapy. Nucleic acids2025
mRNA vaccine expressing enterovirus D68 virus-like particles induces potent neutralizing antibodies and protects against infection.
Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Progress in enterovirus D68-neutralizing antibodies and vaccines.Journal of virology · 2026Review
- Foot-and-mouth disease virus-like particle mRNA vaccine induces strong humoral and cellular immunity.Applied microbiology and biotechnology · 2026Article
- Replication not required: mRNA vaccines take on non-enveloped viruses.Molecular therapy. Nucleic acids · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterovirus D68 (EV-D68) causes respiratory illness in children. It also causes severe paralysis called acute flaccid myelitis (AFM), which has become a global health threat. Here, we generated an mRNA vaccine expressing virus-like particles (VLPs) of EV-D68. We found that the mRNA vaccine elicited potent neutralizing antibodies against EV-D68 in the blood, and the neutralizing titer was superior to that of the inactivated whole virion (IWV) vaccine. The mRNA vaccine showed protective effects against intranasal challenge with EV-D68, and antisera from the vaccinated mice prevented the paralysis caused by EV-D68 infection in neonatal mice. Moreover, the mRNA vaccine induced neutralizing antibodies in the respiratory tract, which is the entry site for EV-D68. Additionally, it attenuated infection with coxsackievirus B3 (CVB3), which belongs to another enterovirus group, via CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.